MannKind Future Growth
Future criteria checks 4/6
MannKind is forecast to grow earnings and revenue by 39.2% and 15.9% per annum respectively while EPS is expected to grow by 38.6% per annum.
Key information
39.2%
Earnings growth rate
38.6%
EPS growth rate
Biotechs earnings growth | 31.8% |
Revenue growth rate | 15.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 378 | 125 | 167 | N/A | 5 |
12/31/2025 | 313 | 74 | 126 | N/A | 6 |
12/31/2024 | 260 | 39 | 188 | N/A | 5 |
12/31/2023 | 199 | -12 | -8 | 34 | N/A |
9/30/2023 | 177 | -31 | -32 | 10 | N/A |
6/30/2023 | 158 | -47 | -57 | -27 | N/A |
3/31/2023 | 128 | -71 | -72 | -61 | N/A |
12/31/2022 | 100 | -87 | -88 | -81 | N/A |
9/30/2022 | 76 | -98 | -98 | -91 | N/A |
6/30/2022 | 66 | -88 | -89 | -78 | N/A |
3/31/2022 | 70 | -94 | -83 | -67 | N/A |
12/31/2021 | 75 | -81 | -73 | -62 | N/A |
9/30/2021 | 81 | -79 | -60 | -49 | N/A |
6/30/2021 | 75 | -86 | -54 | -47 | N/A |
3/31/2021 | 66 | -61 | -35 | -30 | N/A |
12/31/2020 | 65 | -57 | -33 | -28 | N/A |
9/30/2020 | 63 | -45 | -34 | -33 | N/A |
6/30/2020 | 62 | -44 | -73 | -72 | N/A |
3/31/2020 | 62 | -46 | -91 | -88 | N/A |
12/31/2019 | 63 | -52 | -91 | -88 | N/A |
9/30/2019 | 63 | -47 | -61 | -58 | N/A |
6/30/2019 | 53 | -61 | -22 | -20 | N/A |
3/31/2019 | 42 | -71 | -28 | -28 | N/A |
12/31/2018 | 28 | -87 | -38 | -38 | N/A |
9/30/2018 | 16 | -110 | -93 | -93 | N/A |
6/30/2018 | 13 | -119 | -102 | -102 | N/A |
3/31/2018 | 12 | -131 | -95 | -95 | N/A |
12/31/2017 | 11 | -117 | -65 | -65 | N/A |
9/30/2017 | 20 | -31 | N/A | -48 | N/A |
6/30/2017 | 180 | 129 | N/A | -47 | N/A |
3/31/2017 | 178 | 134 | N/A | -39 | N/A |
12/31/2016 | 175 | 126 | N/A | -78 | N/A |
9/30/2016 | 162 | -205 | N/A | -88 | N/A |
6/30/2016 | N/A | -364 | N/A | -85 | N/A |
3/31/2016 | N/A | -363 | N/A | -91 | N/A |
12/31/2015 | N/A | -368 | N/A | -57 | N/A |
9/30/2015 | N/A | -128 | N/A | -70 | N/A |
6/30/2015 | N/A | -133 | N/A | 50 | N/A |
3/31/2015 | N/A | -177 | N/A | 44 | N/A |
12/31/2014 | N/A | -198 | N/A | 4 | N/A |
9/30/2014 | N/A | -216 | N/A | 6 | N/A |
6/30/2014 | N/A | -230 | N/A | -127 | N/A |
3/31/2014 | N/A | -203 | N/A | -134 | N/A |
12/31/2013 | N/A | -191 | N/A | -129 | N/A |
9/30/2013 | N/A | -190 | N/A | -123 | N/A |
6/30/2013 | 0 | -182 | N/A | -124 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NNFN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: NNFN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NNFN is expected to become profitable in the next 3 years.
Revenue vs Market: NNFN's revenue (15.9% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: NNFN's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NNFN's Return on Equity is forecast to be high in 3 years time